ArticleVaccine2018
Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV).
Article in Vaccine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Willingness to Vaccinate Against Herpes Zoster and Its Associated Factors Across WHO Regions: Global Systematic Review and Meta-Analysis.JMIR public health and surveillance · 2023Pooled it
- Understanding Primary Care Physician Vaccination Behaviour: A Systematic Review.International journal of environmental research and public health · 2022Pooled it
- Knowledge of Herpes Zoster and Attitudes Toward Vaccination: A Questionnaire-Based Study in Outpatient and Online Settings.Vaccines · 2026Article
- Herpes zoster vaccination: Primary care provider knowledge, attitudes, and practices.Human vaccines & immunotherapeutics · 2025Article
- Knowledge, Attitudes and Practices Survey of Recombinant Zoster Vaccine among Cardiologists and Cardiac Nurses in Italy.Medicina (Kaunas, Lithuania) · 2024Article
- Unraveling Herpes Zoster Vaccine Hesitancy, Acceptance, and Its Predictors: Insights From a Scoping Review.Public health reviews · 2024Article
- Survey of Physician Practices, Attitudes, and Knowledge Regarding Recombinant Zoster Vaccine.Journal of general internal medicine · 2023Article
- Vaccine Hesitancy Counseling-an Educational Intervention to Teach a Critical Skill to Preclinical Medical Students.Medical science educator · 2022Article
- Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States.Ophthalmology · 2021Article
- Physician survey regarding updated PCV13 vaccine recommendations for adults ≥65 years.Journal of the American Geriatrics Society · 2021Article
- Shared Clinical Decision-Making Recommendations for Adult Immunization: What Do Physicians Think?Journal of general internal medicine · 2021Article
- Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018.Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002) · 2021Article
- Knowledge, attitudes, and practices of General Practitioners from the Province of Parma (Northern Italy) towards vaccinations in adults ≥ 65 year-old.Acta bio-medica : Atenei Parmensis · 2019Article
- Advancing regulatory science and assessment of FDA REMS programs: A mixed-methods evaluation examining physician survey response.Journal of clinical and translational science · 2019Article
- Vaccination Capability Inventory of Community, Migrant, and Homeless Health Centers: A Survey Report.Journal of public health management and practice : JPHMPArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe Advisory Committee on Immunization Practices (ACIP) has routinely recommended zoster vaccine live (ZVL) for adults ≥60 since 2008; only 33% of eligible adults received it by 2016. A recombinant zoster vaccine (RZV) was licensed in 2017 and ACIP recommended in January 2018. Our objectives were to assess among primary care physicians (1) practices and attitudes regarding ZVL and (2) awareness of RZV.
methodsWe administered an Internet and mail survey from July to September 2016 to national networks of 953 primary care physicians.
resultsResponse rate was 65% (603/923). Ninety-three % of physicians recommended ZVL to adults ≥60, but fewer recommended it to adults ≥60 with a prior history of zoster (88%), adults > 85 (62%) and adults ≥60 on low-dose methotrexate (42%). Several physicians recommended ZVL in ways that are not recommended by ACIP including to adults 50-59 (50%), adults ≥60 with HIV (33%), and adults ≥60 on high dose prednisone (≥20 mg/day) (27%). Nineteen percent of physicians stocked and administered ZVL and did not refer patients elsewhere for vaccination, 37% did not stock and only referred patients to receive it, and 44% both stocked/administered and referred elsewhere. Twenty-three % (n = 115) of physicians who had ever administered ZVL in the office (n = 490) had stopped, citing primarily financial issues (90%). Only 5% were 'very aware' of RZV.
conclusionsPhysicians report not recommending ZVL to certain ACIP-recommended groups, but report recommending it to some groups for which the vaccine should be avoided. Implementation of recommendations for RZV will need to consider financial barriers and the complex patchwork of office-based and pharmacy delivery ZVL has encountered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.